Skip to main content

Advertisement

Table 1 Additional clinical characteristics and demographic profiles of patients

From: Validation of the Khorana score in acute myeloid leukemia patients: a single-institution experience

Patient Characteristics Value (N = 867)
Patient age
 median (range), y 75 (51–96)
Sex, No. (%)
 Male 565 (65)
 Female 302 (35)
Race, No. (%)
 Caucasian 801 (92)
 African American 18 (2)
 Hispanic 25 (3)
 Other 19 (2)
AML classification, No. (%)
 De novo AML 383 (44)
 Secondary AML 483 (56)
AML risk stratification, No. (%)
 Favorable-risk group 21 (2)
 Intermediate-risk group 485 (56)
 Poor-risk group 266 (31)
History of prior or concurrent cancer, No. (%)
 Hematologic malignancies 34 (4)
 Solid tumors 207 (24)
Prior thrombosis (arterial/venous) 126 (14)
Growth factors, No. (%)
 Before AML diagnosis 167 (19)
 EPO 101 (12)
 G-CSF 58 (7)
 GM-CSF 8 (1)
 Post AML diagnosis 728 (84)
Complete blood counts at diagnosis, No. (range)
 WBC (× 109/L) 3.165 (0.08–413.74)
 Hemoglobin (g/dL) 9.3 (5.6–15.2)
 Platelet (× 109/L) 46 (1–800)
Treatment regimen, No. (%)
 Chemotherapy 250 (29)
 Hypomethylating agent 240 (28)
 Best supportive care 225 (26)
BMI, No. (%)
  ≤ 35 kg/m2 820 (65)
  > 35 kg/m2 47 (5)
  1. Abbreviations: AML acute myeloid leukemia, BMI body mass index, EPO erythropoietin, G-CSF granulocyte colony-stimulating factor, GM-CSF granulocyte-macrophage colony-stimulating factor, WBC white blood cells